Related Experiment Videos
Clinical research on antiangiogenic therapy
R A Kuiper1, J H Schellens, G H Blijham
1Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands.
Pharmacological Research
|March 21, 1998
Summary
Targeting tumor blood vessels, or angiogenesis, is a key anti-cancer strategy. This review covers agents that inhibit angiogenesis and their early clinical results in cancer therapy.
Area of Science:
- Oncology
- Vascular Biology
Background:
- Tumor vasculature is a critical target for anti-cancer therapies.
- Tumor growth and metastasis rely on angiogenesis (new blood vessel formation).
- Inhibiting angiogenesis effectively controls tumor progression.
Purpose of the Study:
- To review agents with anti-angiogenic activity.
- To summarize early clinical experiences with these anti-angiogenic drugs.
Main Methods:
- Literature review of anti-angiogenic agents.
- Analysis of pre-clinical and clinical study data.
Main Results:
- Several natural and synthetic compounds show anti-angiogenic potential.
- Early clinical studies are evaluating these agents for cancer treatment.
Conclusions:
- Targeting tumor vasculature via angiogenesis inhibition is a promising anti-cancer approach.
- Further clinical evaluation of anti-angiogenic agents is ongoing.